Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTABARBITAL vs PHRENILIN FORTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.
Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.
Sedative,Hypnotic for short-term treatment of insomnia,Preoperative sedation
Tension-type headache
50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.
1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.
Terminal elimination half-life is 30-50 hours in adults, which may be prolonged in elderly or patients with hepatic impairment, leading to accumulation with repeated dosing.
Butalbital: 35-50 hours (long-acting barbiturate). Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose. Caffeine: 3-7 hours (average 5 hours); prolonged in liver disease.
Hepatic metabolism via cytochrome P450 enzymes (primarily CYP2C9 and CYP3A4); undergoes hydroxylation and glucuronidation; active metabolites include hydroxybutabarbital.
Butalbital: primarily hepatic via CYP2C19 and CYP2C9. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A9, UGT2B15), sulfation, and CYP2E1 (minor). Caffeine: hepatic via CYP1A2.
Primarily renal, with approximately 60-80% of the dose eliminated as metabolites (mostly hydroxylated and conjugated) and less than 5% as unchanged drug. Minor biliary/fecal excretion occurs (<10%).
Butalbital: ~60-70% renal as unchanged drug and metabolites. Acetaminophen: ~85% renal as sulfate and glucuronide conjugates (2-4% unchanged). Caffeine: ~1% renal unchanged; major metabolites are paraxanthine, theobromine, and theophylline eliminated renally.
Approximately 20-25% bound to plasma proteins, predominantly albumin.
Butalbital: ~30% bound to plasma proteins. Acetaminophen: <5% bound at therapeutic levels. Caffeine: ~35% bound to albumin.
Approximately 1.0 L/kg, indicating distribution throughout total body water and extensive tissue binding.
Butalbital: ~0.8 L/kg (widely distributed). Acetaminophen: ~1 L/kg. Caffeine: ~0.6 L/kg.
Oral bioavailability is nearly 100% (50-70% reported in some texts, but butabarbital is completely absorbed; first-pass metabolism is minimal).
Oral bioavailability: Butalbital 90% (well absorbed); Acetaminophen 85-95%; Caffeine 99% (essentially complete).
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50%.
Not formally established. Acetaminophen component: avoid in severe renal impairment (Cr Cl <10 m L/min) due to accumulation of metabolites; adjust dosing interval to every 6 hours for Cr Cl 10-50 m L/min.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): reduce dose to 1 capsule every 6 hours and monitor for hepatotoxicity.
Children 2-6 years: 25-50 mg orally 3-4 times daily; children 6-12 years: 50-100 mg orally 3-4 times daily; maximum 200 mg/day.
Not recommended for pediatric patients due to risk of butalbital dependence and acetaminophen hepatotoxicity. Alternative agents preferred.
Initiate at 25-50 mg orally 3 times daily; increase cautiously to avoid excessive sedation and falls, maximum 200 mg/day.
Initiate at 1 capsule every 6 hours; maximum 4 capsules daily. Renal and hepatic function should be monitored, and dose adjusted accordingly.
Butabarbital has no FDA boxed warning.
Acetaminophen may cause severe hepatic injury, including acute liver failure, sometimes resulting in liver transplant or death. Butalbital is habit forming and may be abused; limit use to intermittent treatment.
Risk of dependence, tolerance, and withdrawal symptoms upon discontinuation; respiratory depression, especially with high doses or in patients with respiratory compromise; CNS depression may impair ability to drive or operate machinery; concomitant use with other CNS depressants (e.g., alcohol, opioids) increases risk of profound sedation and respiratory depression; geriatric patients may be more sensitive to effects; use with caution in patients with hepatic or renal impairment.
Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g/day. Risk of dependence, abuse, and withdrawal with butalbital. CNS depression; avoid alcohol and other sedatives. Renal impairment, hepatic impairment.
Hypersensitivity to barbiturates; porphyria (can exacerbate); severe respiratory insufficiency; history of addiction to sedative-hypnotics; acute or chronic pain (may cause paradoxical excitement); pregnancy (especially third trimester) and lactation.
Hypersensitivity to any component; porphyria; severe hepatic impairment; concomitant MAO inhibitor use (or within 14 days)
Grapefruit juice may decrease metabolism of butabarbital; avoid concurrent consumption. Alcohol increases CNS depression and should be avoided. No specific food restrictions otherwise.
Avoid alcohol and caffeine-containing foods/drinks (e.g., coffee, tea, cola, chocolate) as they may increase side effects like jitteriness or insomnia. Grapefruit juice may alter caffeine metabolism; consider avoiding. No significant food interactions with acetaminophen or butalbital.
First trimester: Associated with increased risk of major congenital malformations, specifically oral clefts (relative risk ~2.0). Second/third trimester: Chronic use may lead to fetal dependence and withdrawal syndrome; neonatal respiratory depression if used near term; increased risk of neurobehavioral effects. Barbiturates cross the placenta rapidly.
First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third trimester: Butalbital may cause fetal dependence and withdrawal; acetaminophen safe at therapeutic doses. Avoid in pregnancy unless benefit outweighs risk.
Butabarbital is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.4–0.6. With therapeutic doses, infant serum levels are usually low; however, chronic high maternal doses may cause sedation or withdrawal in the nursing infant. Caution is recommended; alternate agents may be preferred if infant sedation occurs.
Acetaminophen: minimal excretion, M/P ratio ~0.9, considered compatible. Butalbital: excreted in breast milk, M/P ratio ~0.6, may cause infant drowsiness or withdrawal; caution advised. Caffeine: M/P ratio ~0.5-0.8, generally safe in moderate amounts.
Pregnancy can alter butabarbital pharmacokinetics due to increased hepatic metabolism and volume of distribution. Serum concentrations may decrease; therapeutic drug monitoring is recommended if used chronically. Dose adjustments may be necessary to maintain efficacy, but due to risks, use is generally avoided. If used, start with lowest effective dose and monitor for clinical response and toxicity.
Increased renal clearance and volume of distribution in pregnancy may reduce acetaminophen and caffeine levels; no standard dose adjustment recommended. Butalbital: increased clearance due to hepatic enzyme induction and increased Vd; monitor for reduced efficacy; adjust dose based on clinical response. Avoid supratherapeutic doses.
Butabarbital is a short-acting barbiturate with rapid onset. It is primarily used for sedation and insomnia but has high abuse potential. Avoid use in patients with porphyria, severe hepatic impairment, or respiratory insufficiency. Abrupt discontinuation after prolonged use may precipitate withdrawal including seizures. Barbiturates induce CYP3A4 and other hepatic enzymes, reducing efficacy of oral contraceptives, warfarin, and corticosteroids. Use with caution in elderly due to increased risk of falls and cognitive impairment.
Phrenilin Forte is a combination of butalbital, acetaminophen, and caffeine used for tension-type headaches. Butalbital is a barbiturate with high abuse potential; limit to short-term use. Acetaminophen hepatotoxicity risk increases with chronic alcohol use. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of dependence or withdrawal. Avoid in patients with porphyria or severe hepatic impairment.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop taking suddenly as withdrawal reactions such as anxiety, tremors, or seizures can occur.,May cause drowsiness or dizziness; do not drive or operate machinery until you know how this medicine affects you.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, opioids) as they increase risk of severe sedation and respiratory depression.,Use effective contraception while taking this medication as it may reduce hormonal contraceptive effectiveness.,Store in a secure place away from children and others, as it can cause dependence and is habit-forming.
Take only as prescribed; do not exceed recommended dose due to risk of liver damage from acetaminophen.,Avoid alcohol while taking this medication to prevent liver toxicity.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Do not use with other products containing acetaminophen to avoid overdose.,If you have a history of substance abuse, inform your doctor; this drug can be habit-forming.,Notify your doctor if you experience signs of liver problems (e.g., yellowing of skin/eyes, dark urine) or symptoms of withdrawal (e.g., anxiety, insomnia, tremors).,Store at room temperature away from moisture and heat.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTABARBITAL vs PHRENILIN FORTE, answered by our medical review team.
BUTABARBITAL is a Barbiturate that works by Butabarbital is a barbiturate that acts as a central nervous system depressant. It enhances the activity of GABA, an inhibitory neurotransmitter, by binding to the GABA-A receptor and prolonging the opening of chloride ion channels, leading to neuronal hyperpolarization and reduced excitability.. PHRENILIN FORTE is a Barbiturate Combination Analgesic that works by Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTABARBITAL and PHRENILIN FORTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTABARBITAL is: 50-100 mg orally or intramuscularly 3-4 times daily; maximum 400 mg/day.. The standard adult dose of PHRENILIN FORTE is: 1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTABARBITAL and PHRENILIN FORTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTABARBITAL is classified as Category C. First trimester: Associated with increased risk of major congenital malformations, specifically oral clefts (relative risk ~2.0). Second/third trimester: Chronic use may lead to fe. PHRENILIN FORTE is classified as Category C. First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.